Bone loss associated with hyperprolactinemia in patients with schizophrenia: Are there gender differences?

Clinical Schizophrenia and Related Psychoses

Volumn 7, Issue 3, 2013, Pages 115-123

  Kinon, Bruce J ^a   Liu Seifert, Hong ^a   Stauffer, Virginia L ^a   Jacob, Jayanthi ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Antipsychotic Drugs; Bone Mineral Density; Gender Differences; Hyperprolactinemia; Schizophrenia

Indexed keywords

AMINO TERMINAL TELOPEPTIDE; CHLORPROMAZINE; FLUPHENAZINE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LOXAPINE; MESORIDAZINE; MOLINDONE; OSTEOCALCIN; PERPHENAZINE; PIMOZIDE; PROLACTIN; RISPERIDONE; SEX HORMONE; TESTOSTERONE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; CONTROLLED STUDY; ECHOGRAPHY; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; OSTEOLYSIS; PREVALENCE; SCHIZOPHRENIA; SEX DIFFERENCE; TREATMENT DURATION;

ADULT; ANTIPSYCHOTIC AGENTS; BONE DENSITY; BONE RESORPTION; CROSS-SECTIONAL STUDIES; ESTRADIOL; FEMALE; HUMANS; HYPERPROLACTINEMIA; HYPOGONADISM; MALE; MENOPAUSE; MIDDLE AGED; RISPERIDONE; SCHIZOPHRENIA; SEX CHARACTERISTICS; SEX FACTORS; TESTOSTERONE;

EID: 84884882301     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.KISE.020113     Document Type: Article

References (54)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285(6):785-795.
2. Miller MJ. The importance of screening for osteoporosis in mental health settings. Clin Schizophr Relat Psychoses 2009; 3(3):155-160.
3. Fitzpatrick LA. Secondary causes of osteoporosis. Mayo Clin Proc 2002; 77(5):453-468. (Pubitemid 34465153)
4. Halbreich U, Kinon BJ, Gilmore J.A., Kahn LS Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003; 28(SUPPL. 1):53-67. (Pubitemid 36015661)
5. Maguire GA. Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences. J Clin Psychiatry 2002; 63(SUPPL. 4):56-62. (Pubitemid 34242111)
6. Bushe C, Shaw M, Peveler RC A review of the association between antipsychotic use and hyperprolactinemia. J Psychopharmacol 2008; 22(2 Suppl):46-55.
7. Bostwick JR, Guthrie SK, Ellingrod VL Antipsychotic-induced hyperprolactinemia. Pharmacotherapy 2009; 29(1):64-73.
8. Keely EJ, Reiss J P, Drinkwater DT, Faiman C. Bone mineral density, sex hormones, and long-term use of neuroleptic agents in men. Endocr Pract 1997; 3(4):209-213.
9. Hummer M, Malik P, Gasser R.W., Hofer A., Kemmler G, Moncayo Naveda RC, et al Osteoporosis in patients with schizophrenia. Am J Psychiatry 2005; 162(1):162-167. (Pubitemid 40095686)
10. Meyer JM, Lehman D. Bone mineral density in male schizophrenia patients: a review. Ann Clin Psychiatry 2006; 18(1):43-48.
11. Clement-Lacroix P., Ormandy C, Lepescheux L., Ammann P, Damotte D, Goffin V., et al Osteoblasts are a new target for prolactin: analysis of bone formation in prolactin receptor knockout mice. Endocrinology 1999; 140(1):96-105. (Pubitemid 29011146)
12. Coss D, Yang L, Kuo C.B., Xu X., Luben RA, Walker AM Effects of prolactin on osteoblast alkaline phosphatase and bone formation in the developing rat. Am J Physiol Endocrinol Metab 2000; 279(6):E1216-E1225.
13. Naidoo U, Goff DC, Klibanski A. Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 2003; 28(SUPPL. 2):97-108. (Pubitemid 36332232)
14. Kinon BJ, Gilmore JA, Liu H, Halbreich UM Prevalence of hyperprolactinemia in schizophrenia patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology 2003; 28(SUPPL. 2):55-68. (Pubitemid 36332229)
15. Liu-Seifert H., Kinon BJ, Tennant C.J., Sniadecki J., Volavka J. Sexual dysfunction in patients with schizophrenia treated with conventional antipsychotics or risperidone. Neuropsychiatr Dis Treat 2009; 5:47-54.
16. Collinge CA, Lebus G, Gardner M.J., Gehrig L. A comparison of quantitative ultrasound of the calcaneus with dual-energy X-ray absorptiometry in hospitalized orthopaedic trauma patients. J Orthop Trauma 2010; 24(3):176-180.
17. Cepollaro C, Gonnelli S, Montagnani A., Caffarelli C, Cadirni A, Martini S., et al In vivo performance evaluation of the Achilles Insight QUS device. J Clin Densitom 2005; 8(3):341-346. (Pubitemid 41112852)
18. Huopio J, Kroger H, Honkanen R., Jurvelin J, Saarikoski S, Alhava E. Calcaneal ultrasound predicts early postmenopausal fractures as well as axial BMD. A prospective study of 422 women. Osteoporos Int 2004; 15(3):190-195. (Pubitemid 38391533)
19. Khaw KT, Reeve J, Luben R., Bingham S, Welch A, Wareham N., et al Prediction of total and hip fracture risk in men and women by quantitative ultrasound of the calcaneus: EPIC-Norfolk prospective population study. Lancet 2004; 363(9404):197-202. (Pubitemid 38114717)
20. Daens S, Peretz A, de Maertelaer V, Moris M, Bergmann P. Effciency of quantitative ultrasound measurements as compared with dual-energy x-ray absorptiometry in the assessment of corticosteroid-induced bone impairment. Osteoporos Int 1999; 10(4):278-283. (Pubitemid 29476190)
21. Drozdzowska B, Pluskiewicz W. Quantitative ultrasound in diagnosis of metabolic bone diseases. Curr Med Imaging Rev 2005; 1(1):67-74.
22. The International Society for Clinical Densitometry. Official Positions web page. Available at: www.iscd.org/Visitors/positions/OfficialPositionsText. cfm. Accessed March 23, 2010.
23. Shepherd JA, Blake GM T-score and z-scores. J Clin Densitom 2007; 10(4):349350.
24. World Health Organization Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series No. 843. Geneva: World Health Organization, 1994.
25. Lofman O, Magnusson P, Toss G., Larsson L. Common biochemical markers of bone turnover predict future bone loss: a 5-year follow-up study. Clin Chim Acta 2005; 356(1-2):67-75. (Pubitemid 40779887)
26. Halbreich U, Rojansky N, Palter S., Hreshchyshyn M, Kreeger J, Bakhai Y., et al Decreased bone mineral density in medicated psychiatric patients. Psychosom Med 1995; 57(5):485-491.
27. Meaney AM, Smith S, Howes O.D., O'Brien M, Murray RM, O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry 2004; 184:503-508. (Pubitemid 38725710)
28. Schlechte JA, Sherman B, Martin R. Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 1983; 56(6):11201123.
29. Schlechte J, Walkner L, Kathol M. A longitudinal analysis of premenopausal bone loss in healthy women and women with hyperprolactinemia. J Clin Endocrinol Metab 1992; 75(3):698-703.
30. Wieck A, Haddad PM Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review. Br J Psychiatry 2003; 182:199-204. (Pubitemid 36286731)
31. Meaney AM, O'Keane V. Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication. J Psychopharmacol 2003; 17(4):455-458. (Pubitemid 38076344)
32. Orwoll ES. Osteoporosis in men. Endocrinol Metab Clin North Am 1998; 27(2):349-367. (Pubitemid 28285868)
33. Kuruvilla A, Peedicayil J, Srikrishna G., Kuruvilla K, Kanagasabapathy AS A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin Exp Pharmacol Physiol 1992; 19(9):603-606.
34. Bushe C, Shaw M. Prevalence of hyperprolactinemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and atypical antipsychotics. J Psychopharmacol 2007; 21(7):768-773. (Pubitemid 47437921)
35. Rao ML, Kolsch H. Effects of estrogen on brain development and neuroprotection-implications for negative symptoms in schizophrenia. Psychoneuroendocrinology 2003; 28(SUPPL. 2):83-96. (Pubitemid 36332231)
36. Abraham G, Paing WW, Kaminski J, Joseph A., Kohegyi E, Josiassen RC Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study. Am J Psychiatry 2003; 160(9):1618-1620. (Pubitemid 41079547)
37. Klibanski A, Biller BM, Rosenthal D.I., Schoenfeld DA, Saxe V. Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 1988; 67(1):124-130.
38. Biller BM, Baum HB, Rosenthal D.I., Saxe VC, Charpie PM, Klibanski A. Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 1992; 75(3):692-697.
39. Levinson DF, Simpson G. Sequelae of neuroleptic malignant syndrome. Biol Psychiatry 1987; 22(2):237-238.
40. Rosen C, Chestnut CH 3rd, Mallinak NJ. The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplemenatation. J Clin Endocrinol Metab 1997; 82(6):1904-1910. (Pubitemid 127495208)
41. Lindsay R, Hart DM, Aitkin J.M., MacDonald EB, Anderson JB, Clarke AC Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment. Lancet 1976; 1(7968):1038-1041.
42. Canuso CM, Goldstein JM, Wojcik J, Dawson R., Brandman D, Klibanski A, et al Antipsychotic medication, prolactin elevation, and ovarian function in women with schizophrenia and schizoaffective disorder. Psychiatry Res 2002; 111(1):11-20. (Pubitemid 34879071)
43. Bergemann N, Parzer P, Mundt C., Auler B. High bone turnover but normal bone mineral density in women suffering from schizophrenia. Psychol Med 2008; 38(8):1195-1201. (Pubitemid 351950152)
44. Smith S, Wheeler MJ, Murray R, O'Keane V. The effects of antipsychotic-induced hyperprolactinemia on the hypothalamic-pituitary-gonadal axis. J Clin Psychopharmacol 2002; 22(2):109-114. (Pubitemid 34289384)
45. O'Keane V., Meaney AM Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? J Clin Psychopharmacol 2005; 25(1):26-31. (Pubitemid 40129379)
46. Hafner H. Gender differences in schizophrenia. Psychoneuroendocrinology 2003; 28(SUPPL. 2):17-54. (Pubitemid 36335819)
47. Seeman M.V. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004; 161(8):1324-1333. (Pubitemid 38989084)
48. Halbreich U, Kahn LS Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology 2003; 28 Suppl 2:1-16. (Pubitemid 36332228)
49. Javaid MK, Holt RI Understanding osteoporosis. J Psychopharmacol 2008; 22(2 Suppl):38-45.
50. O'Keane V. Antipsychotic-induced hyperprolactinemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol 2008; 22(2 Suppl);70-75.
51. Tannirandorn P, Epstein S. Drug-induced bone loss. Osteoporos Int 2000; 11(8):637-659.
52. Seeman M.V. Gender differences in the prescribing of antipsychotic drugs. Am J Psychiatry 2004; 161(8):1324-1333. (Pubitemid 38989084)
53. Yonkers KA, Kando JC, Cole J.O., Blumenthal S. Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 1992; 149(5):587-595.
54. Blake GM, Fogelman I. Role of dual-energy X-ray absorptiometry in the diagnosis and treatment of osteoporosis. J Clin Densitom 2007; 10(1):102-110. (Pubitemid 46199277)